NGS-based RNA-sequencing Market Overview
The NGS-based RNA-sequencing Market is witnessing significant expansion due to the growing focus on genetic research and precision medicine. Valued at USD 3.2 Billion in 2024, the market is projected to reach USD 26.05 Billion by 2035, registering a remarkable CAGR of 21.00% between 2025 and 2035. The increasing adoption of next-generation sequencing in transcriptomics studies and its applications in drug discovery and development are key growth drivers. For more details, you can refer to the NGS-based RNA-sequencing Market report.
Market Size and Forecast
Market Size 2025: USD 3.87 Billion
Market Size 2035: USD 26.05 Billion
CAGR (2025–2035): 21.00%
Historical data from 2019 to 2022 shows a consistent rise in market adoption, driven by technological advancements in sequencing platforms and the increasing demand for high-throughput genomic analysis. Pharmaceutical and biotechnology companies are leveraging RNA-sequencing technologies to optimize drug discovery pipelines and enable personalized medicine approaches.
Key Market Segments
The market is segmented by Product and Service, Technology, Application, End-user, and Region:
By Product and Service:
Reagents & Consumables
Instruments & Sequencers
Software & Services
By Technology:
Short-read Sequencing
Long-read Sequencing
By Application:
Drug Discovery & Development
Cancer Research
Gene Expression Profiling
Biomarker Identification
By End-user:
Academic & Research Institutes
Pharmaceutical & Biotech Companies
Hospitals & Clinics
By Region:
North America
Europe
Asia Pacific
Rest of the World
Regional Insights
North America dominates the market due to advanced genomic research infrastructure and strong funding for precision medicine initiatives.
Europe exhibits steady growth with emphasis on research collaborations and regulatory support for RNA-sequencing technologies.
Asia-Pacific is emerging rapidly due to rising investments in genomics research, particularly in China, Japan, and India.
Rest of the World offers untapped opportunities, especially in genetic research and personalized medicine applications.
Competitive Landscape
Prominent players profiled in the market include Illumina (U.S.), Thermo Fisher Scientific (U.S.), Oxford Nanopore, Agilent Technologies, BGI (China), PerkinElmer (U.S.), QIAGEN (Germany), Eurofins Scientific (Luxembourg), Hoffmann-La Roche Ltd (Switzerland), Takara Bio Inc. (Japan), and Tecan Genomics, Inc. (Switzerland). Key strategies involve technological innovation, expansion of sequencing platforms, partnerships with research institutions, and diversification of product portfolios.
For a detailed sample, check here:
https://www.marketresearchfuture.com/reports/ngs-based-rna-sequencing-market-22119
Key Market Opportunities
Expansion in genetic research initiatives
Adoption of RNA-sequencing in drug discovery and development
Growth in personalized medicine applications
Increasing demand from academic and clinical research institutes
Market Dynamics
Rapid advancements in next-generation sequencing technologies
Growing prevalence of genetic and chronic diseases requiring precise diagnostics
Increasing investments in healthcare infrastructure and genomics research
Rising collaborations between pharmaceutical companies and research organizations
Conclusion
The NGS-based RNA-sequencing Market is poised for strong growth over the next decade, driven by technological innovations, expanding applications in drug discovery, and rising demand for personalized medicine. Companies leveraging these trends can enhance research outcomes, accelerate drug development, and deliver precise therapeutic solutions to meet global healthcare needs.
Related Healthcare Reports-
